Product Information
Registration Status: ActiveSYNAGIS SOLUTION FOR INJECTION 100MG/ML is approved to be sold in Singapore with effective from 2016-11-07. It is marketed by ABBVIE PTE LTD, with the registration number of SIN15112P.
This product contains Palivizumab 100mg/ml in the form of INTRAMUSCULAR INJECTION, SOLUTION. It is approved for INTRAMUSCULAR use.
This product is manufactured by Boehringer Ingelheim Pharma GmbH & Co. KG (BI) in GERMANY.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Description
Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2). The human lightchain sequence was derived from the constant domain of Ck and the variable framework regions of the VL gene K104 withJk-4. Palivizumab is expressed from a stable murine (mouse) myeloma cell line (NS0). Palivizumab is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each), contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF)
Indication
For prophylaxis of respiratory diseases casued by respiratory syncytial virus.
Mechanism of Action
Palivizumab binds to the fusion glycoprotein of RSV. This prevents its binding and uptake by host cellular receptors.
Active Ingredient/Synonyms
anti-RSV | Palivizumab |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.